Ana Mafalda Lourenço

Ana Mafalda Lourenço

Auto-generated profile, based on publicly available information

Ana Mafalda Lourenço

Faculty of Veterinary Medicine, Centre for Interdisciplinary Research in Animal Health (CIISA) University of Lisbon Lisbon Portugal

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2011 in Veterinary Ophthalmology
Verified
Journal Article
Closed access
PDF file
ALAna Mafalda Lourenço‐Martins
Ana Mafalda Lourenço‐Martins
EDEsmeralda Delgado
Esmeralda Delgado
INIsabel Neto
Isabel Neto
MPMaria Conceição Peleteiro
Maria Conceição Peleteiro
MMMário Morais‐Almeida
Mário Morais‐Almeida
MÁMário
Mário

1 June 2001 in Journal of Eukaryotic Microbiology
Verified
Journal Article
Closed access
PDF file
MAMargarida Alves
Margarida Alves
OMOlga Matos
Olga Matos
IFIsabel Fonseca Pereira da Fonseca
Isabel Fonseca Pereira da Fonseca
EDEsmeralda Delgado
Esmeralda Delgado
ALAna M. Lourenço
Ana M. Lourenço
Francisco José Nunes AntunesFrancisco José Nunes Antunes
Francisco José Nunes Antunes

11 July 2003 in Journal of Eukaryotic Microbiology
Verified
Journal Article
Closed access
PDF file
MLMARIA LUISA LObO
MARIA LUISA LObO
ATAna Teles
Ana Teles
MCMargarida Barão Da Cunha
Margarida Barão Da Cunha
JHJoaquim Henriques
Joaquim Henriques
ALAna Mafalda Lourenco
Ana Mafalda Lourenco
OMOlga Matos
Olga Matos

1 February 2016 in Journal of Proteomics
Verified
Journal Article
Closed access
NCNatacha Couto
Natacha Couto
JMJoana Martins
Joana Martins
ALAna Mafalda Lourenço
Ana Mafalda Lourenço
CPConstança Pomba
Constança Pomba
Ana Varela CoelhoAna Varela Coelho
Ana Varela Coelho

11 March 2022 in Revista Portuguesa de Imunoalergologia
Verified
Journal Article
Closed access
MPMarta Pinto
Marta Pinto
MSMaria Silva
Maria Silva
BFBeatriz Fernandes
Beatriz Fernandes
ABAna Filipa Bizarro
Ana Filipa Bizarro
HPHugo Pereira
Hugo Pereira
ALAna Lourenço
Ana Lourenço
Background and objective: Lokivetmab is the first anti-canine interleukin-31 monoclonal antibody approved in the European Union for Canine Atopic Dermatitis (CAD) management. This study aimed to assess the lokivetmab’s efficacy and safety in treating CAD cases from a university reference service, as well as the dog’s owner’s overall opinion regarding therapy. Methods: Eighteen atopic dogs were enrolled to perform two subcutaneous injections of lokivetmab, according to the protocol. In order to determine the efficacy and safety of the treatment, skin lesions, pruritus score, blood count, liver parameters and adverse side effects were evaluated over 56 days. The overall pet owner’s satisfaction about the therapy was assessed at the end of the study, and the number of animals that maintained the treatment three months after the end of the study was considered. Results: There was a significant reduction in pruritus score over the eight weeks, with 76.5% of the dogs showing a significant clinical improvement. Regarding the lesion score, 77.8% of the dogs achieved significant clinical improvement, with 61.1% reaching it in the first 4 weeks. There were no reported adverse side effects or changes in blood tests. Pet owner’s opinion regarding the improvement of both the dog and its family’s quality of life was very positive, and three months after the end of the study, 77.8% of the dogs continued their therapy with lokivetmab. Conclusion: Lokivetmab proved to be extremely effective and safe, in addition to sparing pet owners from at home drug administrations, which also contributes to their high satisfaction degree. The great specificity of this biological therapy makes it one of the most potent and promising in the CAD field.

13 July 2020 in Animal Genetics
Verified
Journal Article
Closed access
PDF file
MDMartina Dettwiler
Martina Dettwiler
FLF. Leuthard
F. Leuthard
ABA. Bauer
A. Bauer
VJVidhya Jagannathan
Vidhya Jagannathan
ALA. M. Lourenço
A. M. Lourenço
MWM. M. Welle
M. M. Welle